Articles tagged "HLA matching"

2020 American Transplant Congress
Failure to Launch; a Multi-Centre Study of Potential Live Donors in Southeast Nigeria
C. G. Okwuonu¹, G. O. Achor², Q. L. Ogana³, C. Kingsley⁴
¹Internal Medicine, Federal Medical Centre, Umuahia, Nigeria, ²Department of Surgery, Federal Medical Centre, Umuahia, Nigeria, ³Internal Medicine, Beatitudes Mediplex and Kidney Care Centre, Umuahia, Nigeria, ⁴Internal Medicine, Beatitudes Mediplex and Kidney Care Centre, Aba, Nigeria
*Purpose: To determine the socio-demographic characteristics of potential living kidney donors, donor motivation, incidental findings on clinical evaluation and some identified factors that precluded eventual…
2020 American Transplant Congress
The Clinical Relevance of cPRA in 0-ABDRDQ Mismatched Kidney Transplants
J. H. Lan¹, D. Chang¹, M. Kadatz¹, J. Gill¹, H. M. Gebel², J. S. Gill¹
¹Medicine, Division of Nephrology, University of British Columbia, Vancouver, BC, Canada, ²Pathology, Emory University, Atlanta, GA
*Purpose: The clinical relevance of immune sensitization as measured by cPRA in kidney transplantation remains uncertain.*Methods: We identified 4,057 adult, first, kidney only transplant recipients…
2020 American Transplant Congress
Compatible Pairs- Providingan Option to Upgrade
V. Chipman¹, M. Cooper², S. Flechner³, G. Hil⁴, D. Leeser⁵, D. Mandelbrot⁶, M. Ronin⁴, D. Segev⁷, S. Syed⁸, A. Thomas⁹, A. Waterman¹⁰, G. R. Roll¹¹
¹Kidney Transplant, UCSF, San Francisco, CA, ²Georgertown, Washington, DC, ³Cleavland Clinic, Cleavland, OH, ⁴NKR, Babylon, NY, ⁵East Carolina Univ, Greenville, NC, ⁶University of Wisconsin, Madison, WI, ⁷Johns Hopkins, Boltimore, MD, ⁸UCSF, San Francisco, CA, ⁹Johns Hopkins, Baltimore, MD, ¹⁰UCLA and Terasaki Research Institute, Los Angeles, CA, ¹¹Surgery, Division of Transplant, UCSF, San Francisco, CA
*Purpose: Compatible pairs (CPs) can enter an exchange program instead of donating directly. These pairs increase transplants (txp) by providing additional donors within an exchange…
2020 American Transplant Congress
Noninvasive Genotyping of Donor’s HLA in Kidney Transplant Patients by Target Capture Sequencing
T. Jiang, L. Shu, F. Liu, H. Liu, J. Ge
AlloDx, Shanghai; Suzhou, China
*Purpose: Antibody-mediated rejection (ABMR) is the major cause of kidney transplant failure, which requires donor-specific antibodies (DSA) for a definitive diagnosis based on Banff 2013.…
2020 American Transplant Congress
The Impact of HLA-DQ Molecular Mismatches on De Novo Occurrence of Donor-Specific Anti-HLA Antibodies after Kidney Transplantation: An Observational Cohort Study
A. Senev¹, M. Coemans¹, V. Van Sandt², E. Van Loon¹, J. Callemeyn¹, B. Sprangers¹, D. Kuypers¹, M. Emonds¹, M. Naesens¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²HILA, Red Cross-Flanders, Mechelen, Belgium
*Purpose: Evaluating HLA molecular mismatches (MM) instead of antigen mismatches might be a better tool to assess donor-recipient HLA incompatibility and provide a better risk…
2020 American Transplant Congress
HLA Molecular Mismatch Analysis in Recipients of Kidney Plus Hematopoietic Stem/Facilitating Cell Transplant Tolerance Induction Protocol
C. Garcia-Sanchez¹, V. Kosmoliaptsis², H. Copley², J. Leventhal¹, S. Ildstad³
¹NU, Chicago, IL, ²Cambridge, Cambridge, United Kingdom, ³U of Louisville, Lousville, KY
*Purpose: To evaluate the potential role of HLA molecular mismatch (MM) analysis in predicting outcomes in a cohort of HLA-mismatched, related and unrelated recipients of…
2020 American Transplant Congress
Impact of Immunogenicity on Kidney Allograft Survival in Patients Treated with Induction Therapy
R. Michael, B. Mierzejewska, D. Bekbolsynov, J. Ortiz, O. Ekwenna, S. Stepkowski
University of Toledo, Toledo, OH
*Purpose: The induction therapy is currently used in the majority of kidney transplant recipients, regardless of their level of donor/recipient compatibility. We examined whether lower…
2020 American Transplant Congress
A Simple HLA Class II Matching Strategy for the Prediction of De Novo Donor-Specific HLA Antibodies
L. G. Hidalgo¹, I. A. Martinez Juarez², L. Morales-Buenrostro³, S. Shojai⁴, P. Campbell⁴
¹Surgery, University of Wisconsin - Madison, Madison, WI, ²Nephrology, Hospital Angeles Pedregal, Mexico City, Mexico, ³Nephrology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
*Purpose: In kidney transplantation, degree of HLA Class II mismatch (MM) between donor and recipient drives the risk to develop de novo DSA (dnDSA). New…
2020 American Transplant Congress
HLA-DR/DQ Molecular Mismatch Dictates Early Risk of De Novo Donor-Specific Antibody Development and Offers a Personalized Approach to Immunosuppression Management in Kidney Transplantation
S. Davis¹, C. Wiebe², K. Campbell¹, C. Anobile³, M. Aubrey³, A. Wiseman¹, E. Pomfret¹, P. Nickerson², J. Cooper¹
¹University of Colorado, Aurora, CO, ²University of Manitoba, Winnipeg, MB, Canada, ³Clinimmune, Aurora, CO
*Purpose: Clinicians have few tools to predict the risk of alloimmune injury in a patient undergoing renal transplantation, as traditional demographic or clinical variables lack…
2020 American Transplant Congress
Identification of the dnDSA Inducing HLA Mismatches Across Multiple Renal Transplant Centers: A 3-Year Longitudinal Analysis of >11,000 HLA Mismatches in 2271 Patients
J. M. Brennan¹, M. D. Stegall², C. A. Schinstock², R. L. Heilman³, L. M. Rebellato⁴, M. D. Samaniego-Picota⁵, D. Lesser⁴, M. J. Ghandi², J. L. Beaumont¹, M. J. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Phoenix, AZ, ⁴East Carolina University, Greenville, NC, ⁵Henry Ford Transplant Institute, Detroit, MI
*Purpose: The presence of a mismatch (MM) between donor and recipient HLA does not always lead to the patient developing a de novo donor-specific anti-HLA…